ECTRIMS 2017 - Postconference Report

23 November 2017

BioPharm Insight attended the recent 2017 meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Paris, 25-28 October. This news service discussed the latest treatments in MS with experts and gathered intelligence on key developments in the space from sources on the sidelines of the conference.

Headlines include:

• MedDay Pharma’s MD1003 splits neurologist opinion on Phase III progressive MS potential based on Phase IIb/III clinical and imaging data
• MedDay Pharmaceuticals’ MD1003 EMA approval hindered by small trial though progressive MS unmet need aids case
• Alkermes’ ALKS 8700 first-month tolerability, GI data encouraging for potential market benefit over Tecfidera in MS – neurologists
• Novartis’ siponimod Phase III SPMS results spark label/uptake questions; unmet need to drive FDA approval – neurologists
• Roche’s Ocrevus additional PML cases in MS not a cause for concern or negative uptake impact despite analyst frets – neurologists
• Roche initiates Ocrevus review after multiple reported patient deaths in multiple sclerosis leave usage, causality concerns and open questions – sources
• Biogen launches internal task force to rethink clinical trial endpoints focused on disability in multiple sclerosis – source
• Merck offers to pay for additional disease-modifying therapies required during Mavenclad therapy for MS in NICE discussions – sources
• Merck’s evobrutinib MS Phase II trial to finish ahead of schedule by late 2018 due to fast enrolment – exec